Human trials begin for Novavax's coronavirus vaccine
Biotechnology company Novavax rolled out its first human trials for its coronavirus vaccine on Tuesday.
Novavax already tested its vaccine on animals in low doses and found it successful, Axios notes. So the Maryland-based company will inject 131 volunteers in the Australian cities of Melbourne and Brisbane, with results of the clinical trial expected to be made public in July.
Phase 1 of the trial is a "randomized, observer-blinded, placebo-controlled trial" that assesses two different dosage sizes of the vaccine among healthy participants age 18 to 59, Novavax said in a press release. If that first phase goes well, Novavax said it expects a second phase to begin "promptly." That second phase will be conducted across several different countries, including the U.S., and across a broader age range.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Novavax shares spiked when markets reopened Tuesday after the holiday weekend, up from $46.11 per share to $54.20. Novavax is among several pharmaceutical companies racing to develop coronavirus vaccines, with Pfizer and Moderna launching human trials earlier this month.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
The importance of discussing and dealing with debt
The Explainer Increasing numbers of people have 'problem debt' – but there are ways to tackle it
By Marc Shoffman, The Week UK Published
-
'Trump heavy on retribution, light on cash'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
Crossword: March 19, 2024
The Week's daily crossword
By The Week Staff Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published
-
FDA moves to ban menthol cigarettes
Speed Read It's been a long time coming
By Devika Rao, The Week US Published